Extra treatment for certain digestive cancers with undetectable ctDNA
Part of Cancer clinical trials.
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV cancer of the esophagus, stomach, pancreas, bile ducts, gallbladder, or duodenum.
- Your primary tumor can be treated with surgery, radiation, or other local therapy.
- Your cancer has spread to no more than 2 places (like liver, lungs, or lymph nodes) that can be completely treated.
- You have had at least 4 months of successful systemic therapy (like chemo) and your ctDNA levels are undetectable on two separate tests.
- You are between 18 and 80 years old, in good general health, and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks a simple blood test to look for tiny traces of cancer DNA after stomach cancer surgery. It aims to see if this test can catch any cancer coming back early, so you can get treatment sooner.
This trial tests whether using a blood test (Signatera) to guide treatment can safely reduce the amount of chemotherapy after surgery for stomach or esophagus cancer. The goal is to see if less treatment is just as effective, based on whether cancer DNA is still detectable in your blood.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This study looks at using a blood test that finds tiny bits of cancer DNA to decide if you need extra chemotherapy after surgery. It aims to make treatment more personalized and reduce side effects for people with locally advanced stomach cancer.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This trial checks whether a blood test after surgery (ctDNA) can help decide if you should receive additional “adjuvant” treatment for stomach, gastroesophageal junction, or lower esophagus cancer that has HER2-positive tumors. It may help reduce the chance of cancer coming back by tailoring therapy to your risk based on the ctDNA result.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.